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Purpose: The effect of neoadjuvant hormonal therapy (NHT) on radical retropubic pros-
tatectomy (RRP) for prostate cancer is various and remains a controversy for urologists. 
We conducted this study to comparatively evaluate whether NHT before RRP is in-
dicated and beneficial in the aspects of postoperative complications, positive surgical 
margin, and biochemical recurrence. 
Materials and Methods: Between September 2006 and December 2009, 69 men were 
scheduled for RRP as a treatment for clinically localized and locally advanced prostate 
cancer and were divided into two groups. Group 1 (n=31, 44.9%) was treated with RRP 
only, and group 2 (n=38, 55.1%) underwent RRP with preoperative NHT. We evaluated 
clinical parameters, surgical parameters, and the positive margin rate in surgical speci-
mens and the biochemical recurrence rate. 
Results: There were no statistical differences in age, body mass index (BMI), pre-
operative biopsy Gleason score, initial serum prostate-specific antigen (PSA) levels, 
International Prostate Symptom Score (IPSS), or quality of life (QoL) between the two 
groups (p＞0.05). We also observed no differences in the transfusion rate, mean cathe-
terization time, or positive margin rate (p＞0.05). However, the mean operative time 
was significantly higher in the RRP with preoperative NHT group than in the other 
group (p=0.034). There was no significant difference in the biochemical recurrence rate 
during the last follow-up according to NHT (p=0.102) or positive surgical margin 
(p=0.473).
Conclusions: These results suggest that there were no clinical benefits to the admin-
istration of NHT before RRP from the viewpoint of biochemical recurrence. 
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INTRODUCTION
Prostate cancer is a major health public problem in men 
and the second leading cause of cancer death and the most 
common malignancy diagnosed in the United States. A to-
tal of 217,730 new prostate cancer cases and 32,050 deaths 
from prostate cancer are projected to occur in the United 
States in 2010 [1]. There are many management options 
for the early stage of prostate cancer, such as watchful wait-
ing, radical prostatectomy, radiotherapy, and hormonal 
therapy, according to patients’ performance status, pa-
tients’ demands, and the doctor-patient relationship. 
However, the choice of management for localized prostate 
cancer has been radical prostatectomy for the complete re-
moval of cancer cells [2]. Prostate cancer is frequently hor-
mone dependent, and therefore anti-androgen therapy has 
been an important aspect of treatment for patients with 
prostate cancer. The goal of neoadjuvant hormonal therapy 
(NHT) before radical prostatectomy is to reduce the pos-
itive margin rate and the disease recurrence rate, but Korean J Urol 2011;52:19-23
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TABLE 1. Patient characteristics
Group 1 (n=31) Group 2 (n=38) p-value
Age
BMI
Gleason score
Initial PSA
IPSS
QoL
Prostate volume
Clinical stage
T1c
T2a
T2b
T2c
T3a
65.3±5.8
23.9±2.5
  6.8±1.0
11.4±8.9
10.9±7.3
  2.4±1.6
27.3±7.3
  1
12
  7
  6
  5
67.3±5.7
23.4±2.3
  7.1±1.2
14.8±8.1
11.9±6.6
  2.7±1.5
30.1±11.4
  3
13
10
  8
  4
0.162
0.371
0.265
0.105
0.547
0.417
0.241
BMI: body mass index, PSA: prostate-specific antigen, IPSS: 
International Prostate Symptom Score, QoL: quality of life 
whether these goals are met remains controversial. Many 
arguments suggest that the apparent down-staging re-
sults from difficulty with the pathological evaluation of the 
neoadjuvantly treated prostatectomy specimen [3,4]. Song 
and Chang showed that most uro-oncologists in Korea per-
form hormonal treatment for patients with locally ad-
vanced or minimally metastatic prostate cancer and per-
form NHT before radical prostatectomy in 55% of cases [5]. 
In addition, many Koreans tend to hesitate to choose an op-
eration for cancer treatment. Similarly, there were many 
cases in our hospital in which surgery was delayed because 
of patient demands. NHT before radical retropubic prosta-
tectomy (RRP) was started as a result of patient desire to 
delay operation in our hospital. Therefore, we conducted 
this study to comparatively evaluate whether NHT before 
RRP is indicated and beneficial. 
MATERIALS AND METHODS
Between September 2006 and December 2009, we retro-
spectively analyzed the medical records of 69 prostate can-
cer patients who were treated with RRP in our hospital. All 
patients were suspected of having prostate cancer on the 
basis of positive results on a digital rectal examination, se-
rum prostate-specific antigen (PSA) levels, and the results 
of transrectal ultrasound (TRUS). All patients underwent 
TRUS-guided prostate biopsy, and prostate cancer was 
confirmed by pathology. A total of 31 patients (group 1, 
44.9%) underwent RRP only, and 38 patients (group 2, 
55.1%) were treated with RRP and a mean of 3 months of 
NHT. NHT was started to delay RRP due to patient 
demands. NHT comprised a combined androgen blockade 
with luteinizing hormone-releasing hormone analogue 
(goserelin acetate, Zoladex
Ⓡ) injections monthly and anti-
androgen (bicalutamide 50 mg, Casodex
Ⓡ) daily. We eval-
uated patient age, body mass index (BMI), preoperative bi-
opsy Gleason score, initial serum PSA levels, International 
Prostate Symptom Score (IPSS), quality of life (QoL), 
TRUS-guided prostate volume, and clinical stage. Clinical 
stage was established by computer tomography, magnetic 
resonance imaging, and bone scanning. All patients were 
younger than 75 years of age and had a serum PSA of less 
than 50 ng/ml. Exclusion criteria included prior treatment 
with radiation therapy, concomitant use of medications 
with antiandrogenic activity, prior history of cancer, or se-
vere renal or hepatic impairment. RRP with pelvic lympha-
denectomies was performed according to the standard 
method. Pelvic lymph node dissection was routinely per-
formed during radical prostatectomy. All of the histological 
slides were sent to the pathologist in our hospital to stand-
ardize histopathological examination. We recorded all pa-
tients’ postoperative pathologic stage. The stage and tumor 
grade were assessed by use of the 2009 TNM staging 
system. The operative time, blood loss, catheterization 
time, transfusion rate, intraoperative and postoperative 
complications, positive margin rate, and biochemical re-
currence rate were compared among the two groups. 
Follow-up evaluations measured serum PSA every 3 
months for 1 year postoperatively and every 6 months 
thereafter. Biochemical recurrence was defined as a serum 
PSA level of 0.2 ng/ml or greater on two consecutive 
evaluations.
SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) was used 
for statistical analysis. The independent-sample t-test was 
used to compare different group variables, and the chi- 
square test was used to compare nominal data. Kaplan- 
Meier curves were used to present survival until bio-
chemical recurrence in the 2 treatment groups. p-values 
less than 0.05 were considered statistically significant.
RESULTS
All patients undergoing NHT showed good tolerance to go-
serelin acetate and bicalutamide. No patients experienced 
severe hepatic dysfunction, renal failure, gastrointestinal 
reactions, or cardiovascular effects. Mean patient age 
(±SD) was 65.3±5.8 and 67.3±5.7 years in the two groups 
(p=0.162). There were no statistical differences in patient 
BMI, Gleason score of prostate biopsy, initial serum PSA 
levels, IPSS, QoL, or mean TRUS-guided prostate volume 
between the two groups. The patients’ characteristics at 
the time of diagnosis are presented in Table 1. The pre-
operative clinical stage was compared between the two 
groups, and the two groups were found to be equally bal-
anced for clinical stage. Also, there were no cases that ex-
tended to the seminal vesicle on magnetic resonance 
imaging. 
There were no statistical differences in postoperative pa-
rameters, such as red blood cell volume reduction, hemo-
globin decrement, catheterization time, transfusion rate, 
or positive margin rate, except for operative time. Also, the 
postoperative pathologic stages were compared between 
the two groups (Table 2). The two groups were also equally 
balanced for pathologic stage. Pelvic lymph node dissection 
showed no lymph node metastasis in any of the patients. Korean J Urol 2011;52:19-23
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TABLE 2. Postoperative parameters
Group 1 (n=31) Group 2 (n=38) p-value
Operative time (hr)
RBC volume 
reduction (ml)
Hemoglobin 
decrement (g/dl)
Catheterization 
time (d)
No. of transfusions 
(%)
No. of positive 
margins (%)
Pathologic stage
T2a
T2b
T2c
T3a
T3b
3.34±0.77
322.2±170.8
2.7±1.5
15.9±3.8
8 (25.8)
8 (25.8)
  5
  5
15
  5
  1
3.76±0.84
325.8±168.3
2.7±1.3
16.0±4.5
11 (28.9)
  8 (21.1)
  6
  8
12
  8
  4
0.034
0.931
0.972
0.928
 0.771
a
 0.642
a
RBC: red blood cell, 
a: statistical analysis by chi-square test
FIG. 1. Kaplan-Meier curves for prostate-specific antigen (PSA) 
recurrence free survival until PSA failure according to treat-
ment regimen. Biochemical recurrence rate does not show any 
significant difference between 2 arms. log-rank test, p=0.102.
Operative time was 3.34±0.77 and 3.76±0.84 hours in the 
two groups. Operative time was longer for the men who re-
ceived NHT than for those who had not received NHT, and 
the difference between the two groups was significant 
(p=0.034). Also, in the Pearson’s correlation analysis, oper-
ative time was positively correlated with cycles of NHT 
(r=0.28, p＜0.019). 
Fig. 1 shows the proportion of men without PSA failure 
during the follow-up period among men treated by RRP 
alone and among those treated by RRP with preoperative 
NHT. During the follow-up period, PSA recurrence-free 
survival was higher among men who had not received NHT 
than among those who had received NHT. The mean bio-
chemical recurrence period was 32±3 months in the 
non-NHT group and was 24±3 months in the NHT group. 
However, there was no significant difference in the bio-
chemical recurrence rate at the last follow-up according to 
NHT (log-rank test, p=0.102) or positive margin rate (log- 
rank test, p=0.473). 
Some postoperative complications were recorded: one 
anastomotic leakage in group 1 and one in group 2. There 
were no anastomotic strictures or rectovesical fistulas. No 
patients had rectal injuries, and there was no mortality in 
this series.
DISCUSSION
Of the management options for prostate cancer, radical 
prostatectomy and radiotherapy are the most widely ac-
cepted treatments for patients with early stage disease 
who require intervention. The main curative form of treat-
ment for localized prostate cancer is radical prostatectomy 
[6]. It is reasonable to offer radical prostatectomy for the 
cure of localized prostate cancer. However, for nearly 66% 
of men undergoing prostatectomy, the preoperative clin-
ical stage underestimates the extent of disease, and the 
positive margin rate may be as high as 30% to 60% [7]. The 
first use of gonadotropin-releasing hormone agonists in 
prostate cancer was for the palliation of metastatic disease 
[8]. The rationale for NHT evolved from the need to de-
crease the high positive margin rate following radical pros-
tatectomy and to reduce the clinical recurrence rate. The 
development of safe, potent, and reversible agents for NHT 
provided a well-tolerated method for inducing prostate 
cancer cell death and tumor regression before radical 
prostatectomy. There is no consensus in the medical liter-
ature, however, as to whether radical prostatectomy after 
NHT is of greater, equal, of lesser difficulty than radical 
prostatectomy in patients who have not received NHT [9]. 
The role of NHT before radical prostatectomy remains 
controversial. According to Monfette et al, an advantage of 
hormonal treatment is a decrease in blood loss and oper-
ative difficulty after hormonal treatment [10]. This point 
of view states that NHT decreases the operative parame-
ters and may make the operation easier. However, Soloway 
et al found that NHT makes the operation more difficult 
because of intense periprostatic reaction together with 
seminal vesicle adhesions, but that this had no effect on op-
erative time or intraoperative bleeding [11]. This point of 
view states that NHT before radical prostatectomy may 
make the operation more difficult. 
In our series, we compared the effect of prolonged NHT 
and no NHT on the outcome of operative parameters and 
found no effect on operative parameters except for oper-
ative time. Mean operative time was 3.34±0.77 and 
3.76±0.84 hours in the two groups. There was a significant 
difference between the two groups (p=0.034). According to 
Macfarlane et al, NHT has no effect on operative parame-
ters [3]. After 3 months of neoadjuvant treatment, 18 pa-
tients with clinical stage B2 or C prostate cancer had an 
average estimated blood loss of 1,238 ml and an average 
operative time of 183 minutes [3]. At the same time, a his-Korean J Urol 2011;52:19-23
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torical control group of 20 patients with pathological stage 
B2 disease had an average blood loss of 1,296 ml and an 
average operative time of 171 minutes, which were similar 
results. Goldenberg et al randomly assigned 192 patients 
to surgery alone (n=91) or a 12-week course of cyproterone 
acetate (n=101) [12]. There were no significant differences 
in surgical difficulty, intraoperative blood loss, or the num-
ber of patients requiring transfusion. Schulman et al com-
pared 400 patients with prostate cancer who were ran-
domly assigned to direct surgery (n=209) or to NHT for 3 
months (n=191) before radical prostatectomy [13]. The 
mean duration of surgery was 159 and 163 minutes, and 
mean blood loss was 1,150 and 1,082 ml, in the direct sur-
gery and NHT before surgery groups, respectively. Meyer 
et al found similar blood loss and shorter operative times 
in 292 patients undergoing more than 3 months of NHT 
than in 388 patients treated with radical prostatectomy 
alone [14]. Similarly, Gleave et al reported a mean blood 
loss of 826 versus 761 ml in the 3- and 8-month groups, re-
spectively, and no major intraoperative morbidity [15]. 
The positive surgical margin rate is an important in-
dependent prognostic factor, and the presence of a positive 
surgical margin was associated with the greatest relative 
risk. Prostate cancer is curable only when treated at an ear-
ly stage, when the tumor is still localized to the prostate 
gland [16]. In fact, most clinical studies show decreases in 
the positive margin rate up to 50% after 3 months of NHT 
[17]. Gao et al compared 31 patients with prostate cancer 
who underwent radical prostatectomy; of these, 12 pa-
tients underwent preoperative hormonal deprivation [18]. 
There was a higher positive surgical margin rate and ex-
tracapsular extension and greater seminal vesicle in-
vasion in the direct radical prostatectomy group than in the 
NHT group before radical prostatectomy (p＜0.05), but 
there were no significant differences in operative time or 
blood loss between the two groups. The mean operative 
time was 3.2±0.4 and 3.8±0.7 hours, and the mean blood 
loss was 760±431 ml and 771±397 ml, in the direct surgery 
and NHT groups, respectively. 
Recently, laparoscopic radical prostatectomy (LRP) has 
emerged as a treatment modality for localized prostate can-
cer that seeks to combine the benefits of a minimally in-
vasive approach. Some studies of NHT on the outcome of 
LRP have been conducted. Androgen deprivation before 
LRP may increase the subjective technical difficulty but it 
does not have any major impact on the outcome of LRP and 
shows no difference in the positive surgical margin rate 
[19-21]. In our series, there was also no difference in the 
positive margin rate (p=0.642). In addition, we observed 
that patients who received NHT for about 3 month before 
RRP had no statistically significant survival advantage 
compared with those treated by RRP alone.
In conclusion, our study showed a difference in the effect 
of NHT before RRP on operative time, which was higher be-
cause of the slightly greater technical difficulty of RRP. 
Also, according to Pearson’s correlation analysis, a pro-
longed NHT cycle can increase the operative time (r=0.28, 
p＜0.019). It is our opinion that NHT before RRP should 
not be performed for several reasons. First, we found that 
RRP was more difficult to execute because of the peripro-
static fibrosis that occurs in response to the apoptosis 
caused by NHT. Second, estimated blood loss, transfusion 
rate, postoperative complications, positive margin rate, 
and the biochemical recurrence rate appeared to be equiv-
alent in the two groups. Third, patients with prostate can-
cer who undergo long-term NHT are at greater risk of devel-
oping dyslipidemia, insulin resistance, and metabolic syn-
drome [22]. These metabolic and physiological changes are 
a direct result of the induced higher risk of cardiovascular 
morbidity and diabetes mellitus [23-25].  Therefore, under-
standing the impact of the use of NHT in localized prostate 
cancer patients is important, and the consequences of NHT 
are worthy of further clinical research.
A limitation of our study is that the sample size of both 
groups was small, and this was a retrospective analysis 
with a short postoperative follow-up period, which allows 
for potential selection bias. Further large, prospective in-
vestigations and long-term follow-up will be required to 
fully evaluate the efficacy results.
CONCLUSIONS
Preoperative NHT may increase the technical difficulty of 
RRP, but our results do not allow us to reach any major 
conclusions. NHT is associated with significant side ef-
fects, such as hot flushes and gynecomastia, metabolic syn-
drome, and cardiovascular morbidity, and has cost 
implications. The decision to use hormone therapy should, 
therefore, be made at a local level, between the patient and 
the clinician and should take into account the clinical bene-
fits, toxicity, and cost. We suggest that more research is 
needed to guide the choice, the duration, and the schedule 
of NHT and the impact of long-term hormone therapy on 
toxicity and the patient’s QoL.
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